Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which completed Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Corxel Pharmaceuticals to develop and commercialize etripamil. Milestone Pharmaceuticals Inc.was incorporated in 2003 and is headquartered in Montréal, Canada.

Milestone Pharmaceuticals Inc.

An update from Milestone Pharmaceuticals ( ($MIST) ) is now available. On January 26, 2026, Milestone Pharmaceuticals announced that CARDAMYST (etr...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	MIST	$1.97	+0.51%	5.35M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	MIST	$1.97	+0.5%	5.35M
3
4
5
6

MIST

MIST

Get Milestone Pharmaceuticals Inc. Data in Excel

Get Milestone Pharmaceuticals Inc. Data in Excel